Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Total Non-Current Liabilities (2021 - 2025)

Korro Bio (KRRO) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $61.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 3.49% year-over-year to $61.0 million, compared with a TTM value of $61.0 million through Sep 2025, down 3.49%, and an annual FY2024 reading of $64.4 million, up 26.93% over the prior year.
  • Total Non-Current Liabilities was $61.0 million for Q3 2025 at Korro Bio, down from $63.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $64.4 million in Q4 2024 and bottomed at $8.9 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $49.1 million, with a median of $53.8 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities crashed 83.64% in 2022, then skyrocketed 557.45% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $54.4 million in 2021, then plummeted by 83.64% to $8.9 million in 2022, then surged by 469.01% to $50.7 million in 2023, then increased by 26.93% to $64.4 million in 2024, then fell by 5.23% to $61.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KRRO at $61.0 million in Q3 2025, $63.9 million in Q2 2025, and $61.8 million in Q1 2025.